Spectrum To Complete Levofolinic Acid NDA In Q1 2007 Following Acquisition
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Spectrum hopes to launch the active isomer form of leucovorin, levofolinic acid, in late 2007 following acquisition of the compound from private firm Targent, announced March 20
You may also be interested in...
Adventrx CoFactor To Begin Phase III In Q2 Following SPA Agreement With FDA
Adventrx' Phase III trial of CoFactor will evaluate the folate-based biomodulator's ability to improve the efficacy and safety of the chemotherapeutic agent 5-fluorouracil in patients with metastatic colorectal cancer
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product